Evidence map›Paper›PMID 40126098›Full record

ArticleMolecular oncology2025

Time, the final frontier.

Gautier Follain, Michal Dibus, Omkar Joshi, Guillaume Jacquemet

Abstract read
In one paragraph

Article in Molecular oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Gautier FollainTurku Bioscience Centre, University of Turku and Åbo Akademi University, Finland.
Michal DibusTurku Bioscience Centre, University of Turku and Åbo Akademi University, Finland.
Omkar JoshiTurku Bioscience Centre, University of Turku and Åbo Akademi University, Finland.
Guillaume JacquemetTurku Bioscience Centre, University of Turku and Åbo Akademi University, Finland.ORCID 0000-0002-9286-920X

Funding

HORIZON EUROPE Marie Sklodowska-Curie Actions 101108089Research Council of Finland 337530Research Council of Finland 338537Sigrid Juséliuksen SäätiöSyöpäjärjestöt
6 · The paper itself

Abstract

Cancer's notorious heterogeneity poses significant challenges, as each tumor comprises a unique ecosystem. While single-cell and spatial transcriptomics advancements have transformed our understanding of spatial diversity within tumors, the temporal dimension remains underexplored. Tumors are dynamic entities that continuously evolve and adapt, and relying solely on static snapshots obscures the intricate interplay between cancer cells and their microenvironment. Here, we advocate for integrating temporal dynamics into cancer research, emphasizing a fundamental shift from traditional endpoint experiments to data-driven, continuous approaches. This integration involves, for instance, the development of advanced live imaging techniques, innovative temporal omics methodologies, and novel computational tools.

Indexed as

NeoplasmsAnimalsHumansTumor Microenvironmentcancer heterogeneitycircadian clocklive‐cell imagingmetastasistemporal dynamicstemporal omics

Identifiers

PMID40126098
PMCPMC12330933

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.